760-25-1-050-0154 -Leavenworth CMOP THYROID TABLETS -(VA-25-00022614)
ID: 36C77025Q0079Type: Solicitation
Overview

Buyer

VETERANS AFFAIRS, DEPARTMENT OFVETERANS AFFAIRS, DEPARTMENT OFNATIONAL CMOP OFFICE (36C770)LEAVENWORTH, KS, 66048, USA

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

DRUGS AND BIOLOGICALS (6505)

Original Source

https://sam.gov/opp/1dcd63267b5641e99c0c9388ce147548/view
Timeline
    Description

    The Department of Veterans Affairs is soliciting proposals for the procurement of Armour Thyroid tablets for the Leavenworth Consolidated Mail Outpatient Pharmacy (CMOP) under solicitation number 36C77025Q0079. This Request for Quotation (RFQ) emphasizes the need for specific brand-name pharmaceuticals, with a focus on compliance with federal regulations, including the Drug Supply Chain Security Act and the Buy American Act. The procurement process aims to ensure a reliable supply of essential medications for veterans, with a firm-fixed-price contract expected to be awarded based on fair market evaluations. Interested vendors must submit their quotes by December 27, 2024, at 4:00 PM CST, and can direct inquiries to Jennifer L. Knight at jennifer.knight@va.gov or by phone at 913-684-0162.

    Point(s) of Contact
    Jennifer L Knight
    (913) 684-0162
    jennifer.knight@va.gov
    Files
    Title
    Posted
    S02_JnA_Q0079_allsigned.pdf
    The Department of Veterans Affairs is seeking to procure five specific brand name pharmaceuticals for the Leavenworth Consolidated Mail Outpatient Pharmacy (CMOP) under the Simplified Acquisition Procedures outlined in FAR 13.5. The justification for sole-source procurement highlights that only the unique products can fulfill the requirements established by physician prescriptions, with no substitutions permitted due to clinical evaluations by Pharmacy Benefits Management (PBM). The procurement will be a firm-fixed-price contract, with delivery expected within ten days after receipt of order. Market research, conducted to assess available sources, confirmed that Abbvie, the original equipment manufacturer (OEM) of the specified products, does not have registered small business distributors that meet the necessary criteria under the Non-Manufacturer Rule. Consequently, competition is restricted as no other suppliers can provide the required pharmaceuticals, aligning with regulatory provisions. Although previous contracts involved both large and small businesses, only qualified vendors complying with Drug Supply Chain Security Act requirements will be solicited. The anticipated cost is expected to be fair based on historical data and market evaluations, ensuring compliance with procurement guidelines. Overall, this acquisition underlines the VA's commitment to providing specific medications to veterans while adhering to regulatory and market procedures.
    S02_Pre_Sol_36C77025Q0079_final_.pdf
    The Department of Veterans Affairs is issuing a presolicitation notice for the procurement of Armour Thyroid tablets for the Leavenworth CMOP facility, located at 5000 S. 13th Street, Leavenworth, Kansas. The solicitation number for this request is 36C77025Q0079, with bids due by December 27, 2024, at 4 PM Central Time. This contract is classified under the product service code 6505 (Drug and Biologicals) and the NAICS code 325412 (Pharmaceutical Preparation Manufacturing). A total of five different Armour Thyroid tablet variants, ranging from 30-180mg, are required in specific quantities and packaging configurations. Vendors must be registered in SAM.gov and submit their proposals via email, including essential documentation such as the signed SF1449 solicitation cover page, pricing schedule, applicable licenses, and a Buy American Act Certificate if necessary. Timely and compliant submissions are critical, as incomplete packages will be rejected. This effort underscores the VA’s commitment to ensuring a stable supply of essential medications for veterans' care while promoting compliance with federal regulations.
    S02_Pricing Schedule_Q0079.xlsx
    The document pertains to a Request for Quotation (RFQ) for pharmaceutical supplies from the Leavenworth CMOP, with a specific focus on the procurement of various dosages of Armour Thyroid tablets. The RFQ identifies necessary documentation, including a signed solicitation cover page (SF1449), a quote spreadsheet, and compliance with the Buy American Act (BAA). Vendors must submit their quotes by December 27, 2024, by 4:00 PM CST, with a requirement for only one submission per vendor. Key products listed include multiple strengths of Armour Thyroid tablets, with specific quantities requested. Each submission must detail unit pricing, total pricing, and product expiration dates, ensuring a minimum shelf life of one year from delivery. Additional requirements include a state wholesale distributor license, and if applicable, a subcontracting plan. This RFQ reflects government efforts to secure essential pharmaceuticals, ensuring compliance with federal regulations and prioritizing quality supply chains for healthcare provisions. Overall, it serves the objective of facilitating a streamlined procurement process while adhering to regulatory stipulations.
    S02_RFQ_36C77025Q0079_.pdf
    The document outlines a federal Request for Proposal (RFP) from the Department of Veterans Affairs (VA), specifically for the acquisition of pharmaceutical products for the Leavenworth Consolidated Mail Outpatient Pharmacy (CMOP). It specifies that the solicitation (number 36C77025Q0079) is open to all businesses, but emphasizes a goal for small business participation. The RFP includes instructions for submissions, including the requirement for a signed Standard Form 1449 and an Excel pricing schedule. Key components of the RFP involve detailing the specific pharmaceutical items requested, delivery schedules, and adherence to labeling standards such as bar coding requirements compliant with industry regulations. Additionally, it establishes conditions regarding recalls, product quality, and compliance with the Drug Supply Chain Security Act. The RFP is meticulously structured, including sections on general terms and conditions, price/cost schedules, and delivery expectations. The document stresses the importance of compliance with various federal regulations, including FAR and VAAR clauses. This procurement process exemplifies the government's commitment to sourcing pharmaceutical supplies while promoting transparency, process adherence, and support for small businesses within the federal contracting framework.
    Similar Opportunities
    6505--Dimethyl Fumarate Capsules
    Buyer not available
    The Department of Veterans Affairs (VA) is seeking offers for the procurement of Dimethyl Fumarate Capsules (120MG and 240MG delayed-release) through solicitation 36E79726R0003. This contract aims to establish a reliable supply source for these pharmaceutical products to support VA, Department of Defense (DoD), Indian Health Service (IHS), and Bureau of Prisons (BOP) facilities, with a contract structure that includes a one-year base ordering period and four one-year options. The products are critical for treating specific medical conditions, and offerors must comply with stringent requirements, including FDA regulations, Drug Supply Chain Security Act (DSCSA) compliance, and the provision of unique National Drug Codes (NDCs). The deadline for submitting offers has been extended to December 9, 2025, at 2:30 PM CST, and interested parties can contact Contract Specialist Kenneth Lay at Kenneth.Lay@va.gov for further information.
    6505--Biologics by McKesson Specialty Pharmacy (Lenalidomide) (VA-26-00016920)
    Buyer not available
    The Department of Veterans Affairs is seeking qualified suppliers to provide Lenalidomide, a pharmaceutical product, for the Oscar G. Johnson VA Medical Center located in Iron Mountain, MI. This procurement will be conducted through a Brand Name or Equal Request for Quotation (RFQ) under firm-fixed price terms, following FAR Part 13 Simplified Acquisition Procedures. Lenalidomide is crucial for treating certain conditions, making this procurement significant for patient care within the VA system. Interested offerors must submit an itemized quote along with sufficient technical documentation via email to arneil.genus@va.gov by 3 p.m. Central on December 1, 2025, as telephone inquiries will not be accepted.
    Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
    Buyer not available
    The Department of Defense (DoD) is soliciting quotes for pharmaceutical agents as part of its Uniform Formulary Blanket Purchase Agreement (UF BPA) and Uniform Formulary Additional Discount Program (UF ADP) through the Defense Health Agency (DHA). This procurement aims to establish an effective pharmacy benefits program for the Military Health System (MHS), focusing on the clinical and cost-effectiveness of drugs to determine their classification within the formulary. The P&T Committee will review newly approved drugs, including agents for pulmonary, gynecological, endocrine, atopy, skeletal muscle relaxants, and pain management, with quotes due by December 9, 2025, ahead of the committee meeting scheduled for February 4-5, 2026. Interested manufacturers should contact Stephanie Erpelding or Tracy Banks for further details and ensure compliance with submission requirements outlined in the RFQ HT9402-26-Q-9102.
    NATIONAL OPERATIONAL/MAILING SUPPLIES
    Buyer not available
    The Department of Veterans Affairs is seeking proposals for a five-year Indefinite-Delivery, Indefinite-Quantity (IDIQ) contract to supply operational and mailing supplies for seven Consolidated Mail Outpatient Pharmacy (CMOP) locations across the United States. This procurement includes a variety of essential items such as resealable bags, corrugated boxes, durable poly mailers, and child-resistant medical pouches, all of which must meet stringent specifications for safety and compliance with postal regulations. The contract aims to standardize purchasing processes, ensure fair pricing, and maintain high-quality service for the delivery of Veteran prescriptions. Interested vendors should contact Kelly L Mann at kelly.mann@va.gov or Larry Zaritz at larry.zaritz@va.gov, with a guaranteed minimum award of $50,000 and a maximum aggregate value of $49 million per contract. Proposals must be submitted by the specified deadlines, and vendors are required to be registered in SAM.gov.
    6505--Zonisamide Capsules
    Buyer not available
    The Department of Veterans Affairs (VA) intends to issue a Request for Proposal (RFP) for the unrestricted procurement of Zonisamide Capsules, which will serve various federal entities including the Department of Defense (DoD), Bureau of Prisons (BOP), Indian Health Service (IHS), and Federal Health Care Center (FHCC). The contract will be awarded to a single offeror capable of providing an uninterrupted supply of the specified medications, with a contract period of one year and four optional one-year extensions. The procurement is critical for ensuring the availability of these pharmaceutical products, which are essential for patient care within the VA and other federal health facilities. Interested parties should monitor SAM.gov for the solicitation, expected to be issued around December 15, 2025, with a closing date of December 30, 2025, and may direct inquiries to Chris Carthron at Christopher.Carthron@va.gov.
    Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/ Uniform Formulary Additional Discount Program
    Buyer not available
    The Department of Defense (DoD) is seeking quotations for pharmaceutical agents as part of the Pharmacy Uniform Formulary Blanket Purchase Agreement (UF BPA) and the Uniform Formulary Additional Discount Program (UF ADP) to support the Military Health System (MHS). This procurement aims to establish an effective pharmacy benefits program by evaluating the clinical and cost-effectiveness of various pharmaceutical agents, including oncological and antihemophilic agents, for inclusion in the DoD Uniform Formulary. Interested manufacturers must submit their quotes by January 16, 2026, with a pre-quotation teleconference scheduled for November 20, 2025. For further inquiries, contact Tracy Banks at tracy.e.banks2.civ@health.mil or Stephanie Erpelding at stephanie.j.erpelding.civ@health.mil.
    Radiopharmaceuticals for Temple Texas VA Medical Center
    Buyer not available
    The Department of Veterans Affairs is seeking a contractor to provide radiopharmaceuticals for the Olin E. Teague VA Medical Center in Temple, Texas, through a short-term contract lasting six months. This procurement is critical for the Nuclear Medicine Department, as the radiopharmaceuticals are essential for medical imaging and therapeutic treatments for various carcinomas, with a total estimated procurement cost of $445,000. The urgency of this requirement is underscored by the short shelf-life of the products, necessitating timely delivery to ensure continuous patient care for veterans. Interested vendors can contact Jeffrey Crysler at jeffrey.crysler@va.gov or by phone at 210-617-5300 for further details.
    Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
    Buyer not available
    The Department of Defense, through the Defense Health Agency, is soliciting quotes for the Pharmacy Uniform Formulary Blanket Purchase Agreement and the Uniform Formulary Additional Discount Program, aimed at establishing an effective pharmacy benefits program for the Military Health System. This procurement involves the evaluation and selection of pharmaceutical agents based on their clinical and cost-effectiveness, with a focus on newly approved drugs that will be reviewed by the Pharmacy and Therapeutics Committee in February 2025. Interested vendors must submit their pricing information, including National Drug Codes (NDCs), by December 19, 2024, and are encouraged to participate in a pre-quotation teleconference on December 4, 2024. For further inquiries, vendors can contact Tracy Banks at tracy.e.banks2.civ@mail.mil or Julia Trang at julia.n.trang.civ@health.mil.
    6505--Lenalidomide - Brand Name or Generic
    Buyer not available
    The Department of Veterans Affairs is seeking information from vendors regarding the procurement of Lenalidomide, either in brand name or generic form, for the West Texas VA Health Care System. This sources sought notice aims to gather details on various dosages of Lenalidomide capsules to inform future procurement strategies, potentially leading to either competitive bidding or sole source purchases. Lenalidomide is a critical pharmaceutical used in the treatment of certain cancers and conditions, making this procurement essential for patient care within the VA system. Interested vendors must submit a capability statement by December 5, 2025, at 5:00 PM CST, including their technical capabilities and company information, to Contracting Specialist Matt Lee at matthew.lee5@va.gov or by phone at 210-393-9281.
    DA01--550-26-1-985-0034 InstyMed Dispenser System (VA-26-00024776)
    Buyer not available
    The Department of Veterans Affairs (VA) intends to negotiate a limited source contract for the InstyMed Dispenser System, identified by Solicitation Number 36C25226Q0106. This procurement includes the purchase of the dispenser system and professional installation services, emphasizing that it is not a request for proposal or quote, as no solicitation document is available. The InstyMed Dispenser System is crucial for enhancing medication delivery and management within VA facilities. Interested parties must respond to this notice by December 12, 2025, at 10:00 am CST, and can contact Contracting Officer Vernise L. Newton at vernise.newton@va.gov or by phone at 414-844-4850 for further information.